Advertisement

Topics

ARTEMIS Pharmaceuticals Company Profile

23:17 EST 10th December 2018 | BioPortfolio

ARTEMIS Pharmaceuticals, based in Cologne Germany was founded in 1998 and has made significant advances to provide rapid, efficient and sophisticated techniques for the analysis of gene function in vertebrates.We are a wholly-owned subsidiary of Exelixis Inc., South San Francisco CA (NASDAQ: EXEL), but operate a distinct business model. Our activities are dedicated towards the provision of transgenic mouse generation services, tools and related licenses to the industrial and academic community. We operate on a fee for service basis and have a wide range of collaboration possibilities to provide solutions for our customers. Customers include Merck and Co. Inc., Bayer AG, Sanofi-Aventis, Biovitrum, EVOTEC Neurosciences, Regeneron Pharmaceuticals, Schering AG, Boehringer Ingelheim and a large number of other companies and universities.

Location

Neurather Ring 1
Köln
51063
Germany

Contact

Phone: 49 (0) 221-964 53-10
Fax: 49 (0) 221-964 53-21
Email: info@artemispharma.de


News Articles [327 Associated News Articles listed on BioPortfolio]

Artemis new data on Artemisone shows potent inhibitor of human cytomegalovirus replication in preclinical assays

Artemis Therapeutics, Inc., a pharmaceutical company developing new therapies for the treatment of infectious diseases, including cytomegalovirus and malaria, announced that new data on its lead produ...

Artemis Health Welcomes Mitch Macfarlane as New Chief Operating Officer

SALT LAKE CITY, Nov. 9, 2018 /PRNewswire/ -- Artemis Health, a leading benefits analytics firm, announced today that Mitch Macfarlane has joined the company as Read more...

Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome and Neurotoxicity

EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness th...

Eureka Therapeutics Announces Positive Preliminary Results of ET190L1-ARTEMISTM T-cell China Proof-of-Concept Human Clinical Study in Relapsed and Refractory (r/r) B-cell Lymphoma at ASCO Annual Meeting

No Cytokine Release Syndrome observed to date Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing nove...

Eureka Therapeutics Announces Publication of Preclinical Study Validating its ARTEMIS Platform Designed to Mitigate the Risk of Cytokine Release Syndrome (CRS) and Neurotoxicity

Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of th...

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13...Read More... The post Deals and M&As this week: Aridis Pharmac...

GW Pharmaceuticals plc: GW Pharmaceuticals presents latest cannabidiol oral solution (CBD) data at the 13th European Congress of Epileptology

VIENNA, Austria, Aug. 28, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the development and commercialization of cannabinoid prescr...

Silverado Announces $45 Million Capital Commitment from Artemis Real Estate Partners

Silverado, a leading memory care provider, announced it has received a $45 million investment commitment from Artemis Real Estate Partners. IRVINE, Calif. (PRWEB) June 15, 2018 Silverado today announ...

Drugs and Medications [272 Associated Drugs and Medications listed on BioPortfolio]

Artemis alcohol-free antiseptic foam hand [Artemis Bio-Solutions Inc]

ARTEMIS ALCOHOL-FREE Antiseptic Foam Hand Soap

Artemis alcohol-free antiseptic foam hand sanitizer [Artemis Bio-Solutions Inc]

ARTEMIS ALCOHOL-FREE Antiseptic Foam Hand Sanitizer

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

PubMed Articles [136 Associated PubMed Articles listed on BioPortfolio]

DNA replication stress triggers Rapid DNA Replication Fork Breakage by Artemis and XPF.

DNA replication stress (DRS) leads to the accumulation of stalled DNA replication forks leaving a fraction of genomic loci incompletely replicated, a source of chromosomal rearrangements during their ...

Swimming activity in zebrafish larvae exposed to veterinary antiparasitic pharmaceuticals.

Veterinary antiparasitic pharmaceuticals have been detected in surface waters and several of these pharmaceuticals act on the nervous system on the target organisms implying that neurological effects ...

Chiral pharmaceuticals: Environment sources, potential human health impacts, remediation technologies and future perspective.

Chiral pharmaceuticals (CPs), including non-steroid anti-inflammatory drugs (NSAIDs), β-blockers and some herbicide and pesticides, are widely used in aquaculture, clinical treatment and many other f...

Assessment of 83 pharmaceuticals in WWTP influent and effluent samples by UHPLC-MS/MS: Hourly variation.

The removal efficiency of pharmaceuticals in wastewater treatment plants (WWTPs) is variable and some of these compounds pass these plants almost intact and others presenting a removal efficiency clos...

Letter--Incorporating Real-World Evidence and Patient Value Criteria into Value-Based Frameworks for Relapsed/Refractory Multiple Myeloma.

Orlowski has received research funding from Amgen, BioTheryX, Bristol-Myers Squibb, Celgene Corporation, and Takeda Pharmaceuticals; honoraria from Amgen, Bristol-Myers Squibb, Celgene Corporation, Ja...

Clinical Trials [242 Associated Clinical Trials listed on BioPortfolio]

Clinical Study of ET190L1-ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma

This study is to determine the safety, including potential dose limiting toxicities, of ET190L1-ARTEMIS™ T cells and the duration of in vivo survival of ET190L1-ARTEMIS™ T cells in pat...

MIND: Artemis in the Removal of Intracerebral Hemorrhage

The primary objective of this multicenter randomized controlled study is to compare the safety and efficacy of minimally invasive hematoma evacuation with the Artemis Neuro Evacuation Devi...

Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma

This is a non-randomized, single arm, open-label, single institution, phase I study to determine the maximum tolerated dose (MTD) of ET190L1-ARTEMIS™ T cells in patients ≥ 18 years of ...

Measurements of Myocardial Relaxation Time by MRI During Respiration

Measurement of T2 transversal relaxation time by magnetic resonance has a major interest in cardiac imagery. It has been initially used for quantitative evaluation of heart viability and m...

(ARTEMIS-IPF)Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF

The ARTEMIS-IPF study is for people who have been diagnosed with IPF and are between 40-80 years of age. People who have been diagnosed early in the disease may be more responsive to treat...

Companies [1346 Associated Companies listed on BioPortfolio]

Artemis Health Group

Artemis is the nation’s leading provider of specialty-specific electronic medical record (EMR), workflow and mobile patient engagement solutions to help bridge the gap betwee...

ARTEMIS Pharmaceuticals

ARTEMIS Pharmaceuticals, based in Cologne Germany was founded in 1998 and has made significant advances to provide rapid, efficient and sophisticated techniques for the analysis of gene function in ve...

Artemis International, Inc.

ARTEMISPharmaceuticals GmbH

ARTEMIS has developed the ArteMice™ platform, a combination of rapid and sophisticated gene vector design, efficient and expert ES cell transfection techniques, novel blastocyst injection techniques...

Artemis Search

We have been recruiting in the biotechnology arena since 1987. We offer COntract recruitment, executive search and research services exclusiviely to the biotech industry.

More Information about "ARTEMIS Pharmaceuticals" on BioPortfolio

We have published hundreds of ARTEMIS Pharmaceuticals news stories on BioPortfolio along with dozens of ARTEMIS Pharmaceuticals Clinical Trials and PubMed Articles about ARTEMIS Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ARTEMIS Pharmaceuticals Companies in our database. You can also find out about relevant ARTEMIS Pharmaceuticals Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record